Anagrelide is indicated for:
Population group: both men and women, only adults (18 years old or older)
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
An at risk essential thrombocythaemia patient is defined by one or more of the following features:
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Anagrelide is contraindicated in the following cases: